Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.
Admission levels of a specific protein predict the development of acute kidney injury (AKI) as well as the need for dialysis in patients hospitalized for COVID-19, new research shows.
“This protein, soluble urokinase plasminogen activator receptor (suPAR) is produced by immune cells, and in an earlier study we saw that patients with critical illness who had high levels of this protein had a very high risk of AKI,” senior author Salim Hayek, MD, assistant professor of cardiology, University of Michigan, Ann Arbor, explained to Medscape Medical News.
“So when we started seeing how frequent AKI was in COVID-19, with reports of focal segmental glomerulosclerosis-like pathology, it was natural to think about looking at this protein and now…in patients with COVID-19, we see people with dramatically high suPAR levels with significant kidney injury,” he added.
The